Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Chengdu Kanghong Pharmaceutical Group Co., Ltd. clinical trials
The registry lists 33 studies whose lead sponsor is Chengdu Kanghong Pharmaceutical Group Co., Ltd. or one of 2 companies grouped under it. 10 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 3, 2026.
Keep track of what changes. Save the Chengdu Kanghong Pharmaceutical Group Co., Ltd. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Chengdu Kanghong Pharmaceutical Group Co., Ltd..
- Chengdu Kanghong Biotech Co., Ltd.21 studies →Subsidiary
Something wrong?
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.11 studiesSame company
Something wrong?
- IOPtima Ltd.1 study →Acquired — became part of Chengdu Kanghong Pharmaceutical Group Co., Ltd., Oct 1, 2018 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 33 of 33.
- Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive DisorderNot yet recruitingNCT07741331Phase 3
- A Study of KH607 as Monotherpy in Adults Participants With Major Depressive DisorderNot yet recruitingNCT07741240Phase 3
- A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of KH607 in Healthy Chinese ParticipantsNot yet recruitingNCT07634874Phase 1
- A Phase 1 Study of KHN707 Tablets in Healthy ParticipantsNot yet recruitingNCT07557537Phase 1
- First-In-Human Study of KHN922 for InjectionNot yet recruitingNCT07514975Phase 1/2
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Efficacy and Safety of KHN702 Tablets in Moderate to Severe Post-operative Pain SubjectsNot yet recruitingNCT07277933Phase 1
- A Phase 1 Study of KHN702 Tablets in Healthy SubjectsNot yet recruitingNCT07044960Phase 1
- First-In-Human Study in Participants With Advanced Solid TumorsNot yet recruitingNCT06885645Phase 1
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute SchizophreniaNot yet recruitingNCT06589817Phase 3
- Phase 1 Study of KH607 TabletsRecruitingNCT06393803Phase 1
- A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Woman With Postpartum DepressionCompletedNCT07096791Phase 2
- A Phase 2 Study to Evaluate Efficacy and Safety of KH607 Tablets in Adult Participents With Major Depressive DisorderCompletedNCT07101120Phase 2
- A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMDCompletedNCT01436864Phase 3
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World DataStatus unknownNCT04985448
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein OcclusionCompletedNCT03108352Phase 3
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Conbercept Ophthalmic Injection for Patients of Central Retinal Vein OcclusionCompletedNCT03223714Phase 3
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of RetinoblastomaStatus unknownNCT04990271Phase 2
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)TerminatedNCT03577899Phase 3
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)TerminatedNCT03630952Phase 3
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line TherapyStatus unknownNCT04555304Phase 2
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal NeovascularizationStatus unknownNCT04215393Phase 1
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal VasculopathyStatus unknownNCT03244657Phase 4
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed ConditionStatus unknownNCT03232710Not applicable
- The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)Status unknownNCT03159884Phase 4
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word（STONE）Status unknownNCT03054818
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)Status unknownNCT02194634Phase 3
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMDCompletedNCT01157715Phase 2
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)Status unknownNCT02098720Phase 2
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNVStatus unknownNCT01809223Phase 3
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein OcclusionStatus unknownNCT01809236Phase 2
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- A Study Assessing the Safety and Efficacy of Multiple Intravitreal KH902 in Patients With CNV Due to AMDCompletedNCT01242254Phase 1/2
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Safety and Efficacy by Multiple Injection of KH902 in Patients With Diabetic Macular Edema (DME)CompletedNCT01324869Phase 1/2
Sponsor listed in the registry: Chengdu Kanghong Biotech Co., Ltd.
- Evaluation of OT-135P (IOPtiMateTM) : Beam Manipulating System for CO2 Laser Assisted Non-Penetrating Glaucoma SurgeryStatus unknownNCT01059162Not applicable
Sponsor listed in the registry: IOPtima Ltd. · First submitted before IOPtima Ltd. became part of Chengdu Kanghong Pharmaceutical Group Co., Ltd.